Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
Data from the following clinical trials are discussed:
P15.01 - AMG 757, a Half-life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
OA11.04 - Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I/II Trial